ADA Scientific Sessions 2025 Abstract

SGLT2 Inhibitor Prescribing among Patients with Diabetes and Chronic Kidney Disease or Heart Failure in a Primary Care Network

By Nisa M. Maruthur, Lisa R. Yanek, Nestoras Nicolas Mathioudakis, Samantha I. Pitts

Study in peoplePopulations

The paper

Nisa M. Maruthur, Lisa R. Yanek, Nestoras Nicolas Mathioudakis, Samantha I. Pitts

Baltimore

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 910-P

doi.org/10.2337/db25-910-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk